Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras

Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Med
Hlavní autoři: Li, Pengxiang, Wong, Yu‐Ning, Armstrong, Katrina, Haas, Naomi, Subedi, Prasun, Davis‐Cerone, Margaret, Doshi, Jalpa A.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2015
Témata:
Clinical Cancer Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4735783/
https://ncbi.nlm.nih.gov/pubmed/26645975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.574
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky